[go: up one dir, main page]

DK1140191T3 - Kombinationer af ileumgaldesyretransportinhibitorer og nicotinsyrederivater til cardiovaskulære indikationer - Google Patents

Kombinationer af ileumgaldesyretransportinhibitorer og nicotinsyrederivater til cardiovaskulære indikationer

Info

Publication number
DK1140191T3
DK1140191T3 DK99967141T DK99967141T DK1140191T3 DK 1140191 T3 DK1140191 T3 DK 1140191T3 DK 99967141 T DK99967141 T DK 99967141T DK 99967141 T DK99967141 T DK 99967141T DK 1140191 T3 DK1140191 T3 DK 1140191T3
Authority
DK
Denmark
Prior art keywords
combinations
transport inhibitors
cardiovascular indications
acid derivatives
nicotinic acid
Prior art date
Application number
DK99967141T
Other languages
English (en)
Inventor
Bradley T Keller
Kevin C Glenn
Daniel T Connolly
Original Assignee
Searle Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26811675&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1140191(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Searle Llc filed Critical Searle Llc
Application granted granted Critical
Publication of DK1140191T3 publication Critical patent/DK1140191T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK99967141T 1998-12-23 1999-12-17 Kombinationer af ileumgaldesyretransportinhibitorer og nicotinsyrederivater til cardiovaskulære indikationer DK1140191T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11395598P 1998-12-23 1998-12-23
US14255099P 1999-07-07 1999-07-07
PCT/US1999/027950 WO2000038729A1 (en) 1998-12-23 1999-12-17 Combinations of ileal bile acid transport inhibitors and nicotinic acid derivatives for cardiovascular indications

Publications (1)

Publication Number Publication Date
DK1140191T3 true DK1140191T3 (da) 2003-02-24

Family

ID=26811675

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99967141T DK1140191T3 (da) 1998-12-23 1999-12-17 Kombinationer af ileumgaldesyretransportinhibitorer og nicotinsyrederivater til cardiovaskulære indikationer

Country Status (25)

Country Link
US (1) US20030125316A1 (da)
EP (1) EP1140191B1 (da)
JP (1) JP2002533415A (da)
KR (1) KR20010102963A (da)
CN (1) CN1338946A (da)
AR (1) AR037806A1 (da)
AT (1) ATE226448T1 (da)
AU (1) AU776952B2 (da)
BR (1) BR9916567A (da)
CA (1) CA2356664A1 (da)
CZ (1) CZ20012343A3 (da)
DE (1) DE69903661T2 (da)
DK (1) DK1140191T3 (da)
EA (1) EA005030B1 (da)
ES (1) ES2188285T3 (da)
HK (1) HK1044472A1 (da)
HU (1) HUP0104593A3 (da)
IL (1) IL143938A0 (da)
MX (1) MXPA01006467A (da)
MY (1) MY121399A (da)
NO (1) NO20013160L (da)
NZ (1) NZ512533A (da)
PL (1) PL348581A1 (da)
PT (1) PT1140191E (da)
WO (1) WO2000038729A1 (da)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0000772D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
AU2001247331A1 (en) * 2000-03-10 2001-09-24 Pharmacia Corporation Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
ME00145B (me) 2001-01-26 2010-10-10 Merck Sharp & Dohme Upotreba supstituisanih jedinjenja azetidinona za lečenje sitosterolemije
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
WO2003022286A1 (en) 2001-09-08 2003-03-20 Astrazeneca Ab Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
ES2272776T3 (es) 2001-09-21 2007-05-01 Schering Corporation Tratamiento de xantomas con derivados de azetidinona como inhibidores de la absorcion de esterol.
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
WO2004043457A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
DE602004016123D1 (de) 2003-03-07 2008-10-09 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
DE602004018617D1 (de) 2003-03-07 2009-02-05 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
US7192944B2 (en) 2003-03-07 2007-03-20 Schering Corp. Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
SI3023102T1 (sl) 2010-11-04 2018-11-30 Albireo Ab IBAT inhibitorji za zdravljenje jetrnih bolezni
CN103228270B (zh) * 2010-11-08 2016-02-10 阿尔比里奥公司 含ibat抑制剂和胆汁酸结合剂的药物组合
JP2012171911A (ja) 2011-02-22 2012-09-10 Kao Corp Ppar活性化剤
PT2861229T (pt) * 2012-06-15 2021-01-05 Conaris Res Institute Ag Uma composição farmacêutica que contém ácido nicotínico e/ou nicotinamida e/ou triptofano para influenciar positivamente a microbiota intestinal
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
WO2015199147A1 (ja) 2014-06-25 2015-12-30 味の素株式会社 固形製剤及びその着色防止又は着色低減方法
TWI691331B (zh) 2014-09-26 2020-04-21 日商興和股份有限公司 脂質異常症治療劑
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
CN108601744B (zh) 2016-02-09 2022-01-04 阿尔比里奥公司 口服考来烯胺制剂及其用途
ES2874546T3 (es) 2016-02-09 2021-11-05 Albireo Ab Formulación oral de colestiramina y uso de la misma
CA3071182A1 (en) 2017-08-09 2019-02-14 Albireo Ab Cholestyramine pellets, oral cholestyramine formulations and use thereof
WO2019032026A1 (en) 2017-08-09 2019-02-14 Albireo Ab CHOLESTYRAMINE GRANULES, ORAL FORMULATIONS OF CHOLESTYRAMINE AND THEIR USE
WO2019234077A1 (en) 2018-06-05 2019-12-12 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
ES3011850T3 (en) 2018-06-20 2025-04-08 Albireo Ab Crystal modifications of odevixibat
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
CN118834175A (zh) 2019-02-06 2024-10-25 阿尔比里奥公司 苯并硫氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途
CA3127568A1 (en) 2019-02-06 2020-08-13 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
TWI865673B (zh) 2019-12-04 2024-12-11 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
CN114761080B (zh) 2019-12-04 2024-07-23 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
CN114786772B (zh) * 2019-12-04 2024-04-09 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
TWI877263B (zh) 2019-12-04 2025-03-21 瑞典商艾爾比瑞歐公司 苯并噻二氮呯化合物及其作為膽酸調節劑之用途
JP7695242B2 (ja) 2019-12-04 2025-06-18 アルビレオ・アクチボラグ ベンゾチア(ジ)アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
AR120674A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzotiazepina y su uso como ácido biliar
TWI871392B (zh) 2019-12-04 2025-02-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
TWI867107B (zh) 2019-12-04 2024-12-21 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯化合物及其作為膽酸調節劑之用途
JP7665620B2 (ja) 2019-12-04 2025-04-21 アルビレオ・アクチボラグ ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
CA3186857A1 (en) 2020-08-03 2022-02-10 Per-Goran Gillberg Benzothia(di)azepine compounds and their use as bile acid modulators
CA3196488A1 (en) 2020-11-12 2022-05-19 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
CA3198216A1 (en) 2020-12-04 2022-06-09 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
US20230398125A1 (en) 2022-06-09 2023-12-14 Albireo Ab Treating hepatitis
WO2025146508A1 (en) 2024-01-05 2025-07-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2025146507A1 (en) 2024-01-05 2025-07-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19916108C1 (de) * 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung

Also Published As

Publication number Publication date
MY121399A (en) 2006-01-28
MXPA01006467A (es) 2004-03-10
DE69903661T2 (de) 2003-07-03
DE69903661D1 (de) 2002-11-28
EP1140191B1 (en) 2002-10-23
EP1140191A1 (en) 2001-10-10
US20030125316A1 (en) 2003-07-03
HK1044472A1 (zh) 2002-10-25
ATE226448T1 (de) 2002-11-15
EA200100703A1 (ru) 2001-12-24
CN1338946A (zh) 2002-03-06
NO20013160L (no) 2001-08-21
KR20010102963A (ko) 2001-11-17
JP2002533415A (ja) 2002-10-08
PL348581A1 (en) 2002-06-03
NZ512533A (en) 2004-02-27
AU776952B2 (en) 2004-09-30
NO20013160D0 (no) 2001-06-22
BR9916567A (pt) 2001-12-11
CZ20012343A3 (cs) 2001-12-12
IL143938A0 (en) 2002-04-21
AR037806A1 (es) 2004-12-09
HUP0104593A3 (en) 2004-10-28
AU2348100A (en) 2000-07-31
HUP0104593A2 (hu) 2002-03-28
CA2356664A1 (en) 2000-07-06
WO2000038729A1 (en) 2000-07-06
EA005030B1 (ru) 2004-10-28
PT1140191E (pt) 2003-01-31
ES2188285T3 (es) 2003-06-16

Similar Documents

Publication Publication Date Title
DK1140191T3 (da) Kombinationer af ileumgaldesyretransportinhibitorer og nicotinsyrederivater til cardiovaskulære indikationer
DK1140189T3 (da) Kombinationer af ileal galdesyre-transportinhibitorer og fibrinsyrederivater til cardiovaskulære indikationer
DK1140190T3 (da) Kombinationer af ileumgaldesyretransport-inhibitorer og galdesyre-sekvestreringsmidler til cardiovaskulære indikatorer
DK1140187T3 (da) Kombinationer af en IBAT-inhibitor og en MTP-inhibitor til cardiovaskulære indikationer
DK1210503T3 (da) Apparat og fremgangsmåde til forankring af en ekspanderbar rörledning
NO20014823L (no) Heterocyklus-holdige bifenyl-aP2-inhibitorer og metode
DK1058769T3 (da) Apparat til færdiggörelse af en underjordisk brönd og fremgangsmåde til anvendelse af samme
NO20012103D0 (no) Fremgangsmåte for transportering og installering av et ekspanderbart stålrör
NO20015783L (no) Sammensetning og fremgangsmåte for hemming av metallkorrosjon
DK1071745T3 (da) Fremgangsmåde til syntetisering af COX-2-inhibitorer
DK0973997T3 (da) Fremgangsmåde og anordning til sammensætningsanalyse af formationsgasser i borehuller
NO982176D0 (no) Korrosjonsinhiberte organiske syresammensetninger og fremgangsmÕter for anvendelse av disse
DK1114641T3 (da) Fluorethersammensætninger og metoder til inhibering af deres nedbrydning i nærværelse af en Lewis-syre
DK1080794T3 (da) Fremgangsmåde og udstyr til fremstilling af en belægningsfilm
DK70896A (da) Fremgangsmåde og anlæg til fremstilling af spiseispinde
IS1758B (is) Aðferð til nákvæms og sjálfvirks þyngdarsamvals úr raðflæði stykkja
DK1070322T3 (da) Fremgangsmåde og apparat til optagelse af realtidsinformation
NO982177D0 (no) Metallkorrosjonsinhiberte organiske syresammensetninger og fremgangsmÕter for anvendelse av disse
DK1091938T3 (da) Antihistamin piperidinderivativer og mellemprodukter til fremstilling af disse
DK1049382T3 (da) Fremgangsmåde og anordning til overtrækning af artikler
DK1036319T3 (da) Fremgangsmåde til opnåelse af L-dihydroorotsyre og anvendelse deraf
DK1070444T3 (da) Fremgangsmåde og anordning til fremstilling af tyndtlagsstrukturer
IS5151A (is) Aðferð og búnaður til sjálfvirkrar stöflunar á vörubretti
DK0790317T3 (da) Fremgangsmåde baseret på inhibering af phosphataser til detektering og bestemmelse af diarrhoefremkaldende skaldyrsforgiftning
DK1073413T3 (da) Fremgangsmåde og sammensætninger til stabilisering af sammensætninger af acetylcholin